Free Trial

Spruce Biosciences (SPRB) Competitors

Spruce Biosciences logo
$0.06 0.00 (-4.13%)
As of 03:08 PM Eastern

SPRB vs. IMNN, NERV, BCTX, BGXX, AFMD, ABP, LSB, TLPH, PHXM, and ATHA

Should you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include Imunon (IMNN), Minerva Neurosciences (NERV), BriaCell Therapeutics (BCTX), Bright Green (BGXX), Affimed (AFMD), Abpro (ABP), Lakeshore Biopharma (LSB), Talphera (TLPH), PHAXIAM Therapeutics (PHXM), and Athira Pharma (ATHA). These companies are all part of the "pharmaceutical products" industry.

Spruce Biosciences vs.

Imunon (NASDAQ:IMNN) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Imunon presently has a consensus target price of $15.50, indicating a potential upside of 3,590.48%. Spruce Biosciences has a consensus target price of $2.17, indicating a potential upside of 3,487.20%. Given Imunon's stronger consensus rating and higher possible upside, analysts plainly believe Imunon is more favorable than Spruce Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Imunon
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.75
Spruce Biosciences
0 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Imunon had 13 more articles in the media than Spruce Biosciences. MarketBeat recorded 13 mentions for Imunon and 0 mentions for Spruce Biosciences. Imunon's average media sentiment score of 0.31 beat Spruce Biosciences' score of 0.00 indicating that Imunon is being referred to more favorably in the media.

Company Overall Sentiment
Imunon Neutral
Spruce Biosciences Neutral

Imunon has higher earnings, but lower revenue than Spruce Biosciences. Imunon is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Imunon$500K14.74-$19.51M-$1.36-0.31
Spruce Biosciences$4.91M0.52-$47.92M-$1.32-0.05

Imunon has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Spruce Biosciences' return on equity of -62.10% beat Imunon's return on equity.

Company Net Margins Return on Equity Return on Assets
ImunonN/A -230.05% -128.98%
Spruce Biosciences -555.23%-62.10%-47.49%

Imunon has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.49, suggesting that its stock price is 149% more volatile than the S&P 500.

Spruce Biosciences received 14 more outperform votes than Imunon when rated by MarketBeat users. However, 92.59% of users gave Imunon an outperform vote while only 54.17% of users gave Spruce Biosciences an outperform vote.

CompanyUnderperformOutperform
ImunonOutperform Votes
25
92.59%
Underperform Votes
2
7.41%
Spruce BiosciencesOutperform Votes
39
54.17%
Underperform Votes
33
45.83%

4.5% of Imunon shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 5.0% of Imunon shares are held by insiders. Comparatively, 9.1% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Imunon beats Spruce Biosciences on 10 of the 19 factors compared between the two stocks.

Get Spruce Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPRB vs. The Competition

MetricSpruce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.55M$6.49B$5.33B$8.43B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-0.069.1226.8519.75
Price / Sales0.52256.15388.74118.67
Price / CashN/A65.8538.2534.62
Price / Book0.036.436.764.50
Net Income-$47.92M$144.21M$3.23B$248.32M
7 Day PerformanceN/A2.25%1.71%0.48%
1 Month PerformanceN/A4.39%11.16%13.08%
1 Year PerformanceN/A-2.71%17.17%7.36%

Spruce Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPRB
Spruce Biosciences
1.8879 of 5 stars
$0.06
-4.1%
$2.17
+3,487.2%
-91.8%$2.55M$4.91M-0.0620Gap Down
IMNN
Imunon
1.5723 of 5 stars
$0.82
+2.0%
$21.50
+2,535.1%
-72.3%$11.93M$500,000.00-0.4330News Coverage
Analyst Forecast
Gap Up
NERV
Minerva Neurosciences
2.9216 of 5 stars
$1.66
+2.9%
$5.00
+201.9%
-41.1%$11.58MN/A-3.769News Coverage
Analyst Forecast
Gap Up
BCTX
BriaCell Therapeutics
1.3184 of 5 stars
$3.12
+0.3%
$32.00
+925.6%
-84.5%$11.57MN/A-0.238
BGXX
Bright Green
N/AN/AN/AN/A$11.47MN/A-1.002News Coverage
Gap Down
AFMD
Affimed
4.381 of 5 stars
$0.69
+1.2%
$13.50
+1,848.1%
-96.5%$11.16M$877,000.000.00200Analyst Forecast
Analyst Revision
Gap Down
ABP
Abpro
N/A$0.21
+4.9%
$4.00
+1,806.6%
N/A$10.96M$183,000.000.0015Earnings Report
Gap Down
High Trading Volume
LSB
Lakeshore Biopharma
0.7155 of 5 stars
$1.16
+1.8%
N/AN/A$10.80M$672.27M0.00773High Trading Volume
TLPH
Talphera
2.7511 of 5 stars
$0.52
-3.4%
$5.00
+858.8%
-51.8%$10.69M$281,000.00-0.7619
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat
N/AN/A$10.58M$32.66M0.0049
ATHA
Athira Pharma
1.6969 of 5 stars
$0.27
+6.2%
$13.83
+5,023.5%
-89.4%$10.54MN/A-0.0940Gap Down

Related Companies and Tools


This page (NASDAQ:SPRB) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners